Teriparatide (Forteo) is a recombinant form of parathyroid hormone, used in the treatment of some forms of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Teriparatide is administered by injection once a day in the thigh or abdomen. The recommended dose is 20 μg per day.
Teriparatide has an ongoing clinical trial to evaluate its effectiveness in treating the symptoms of osteogenesis imperfecta.
Teriparatide should not be p...
more
Teriparatide (Forteo) is a recombinant form of parathyroid hormone, used in the treatment of some forms of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Teriparatide is administered by injection once a day in the thigh or abdomen. The recommended dose is 20 μg per day.
Teriparatide has an ongoing clinical trial to evaluate its effectiveness in treating the symptoms of osteogenesis imperfecta.
Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget's Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.
The main risk of teriparatide is an increased risk of osteosarcoma. Because of this risk, it is typically used as second line therapy and even then for no more than two years.
Note some very minor side effects: At the first injection, the user may notice a dime-sized circular, light-colored red rash around...
less